Human Cytomegalovirus

  • Joseph L. Waner
Part of the Infectious agents and pathogenesis book series (IAPA)


The modern era of investigation of human cytomegalovirus (HCMV) began with the independent isolation of viruses from three different laboratories(1–3) An insightful historic account of those reports was given by Weller.(4) The AD 169 strain isolated by Rowe et al.(3) from cultures of adenoids and the Davis strain isolated by Weller et al.(2) from a liver biopsy became prototype strains for study. More recently, the Towne strain isolated from urine and studied by Plotkin et al.(5) as a vaccine candidate joined AD 169 and Davis as the three most studied strains of HCMV.


Natural Killer Human Cytomegalovirus Cytomegalovirus Infection Natural Killer Activity HCMV Infection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Smith, M. G., Propagation in tissue cultures of a cytopathogenic virus from human salivary gland virus (SGV) disease, Proc. Soc. Exp. Biol. Med. 92:424–430 (1956).PubMedGoogle Scholar
  2. 2.
    Weller, T. H., J. C. Macauley, J. M. Craig, and P. Wirth, Isolation of intranuclear inclusion producing agents from infants with illnesses resembling cytomegalic inclusion disease, Proc. Soc. Exp. Biol. Med. 94:4–12 (1957).PubMedGoogle Scholar
  3. 3.
    Rowe, W. P., J. W. Hartley, S. Waterman, H. C. Turner, and R. J. Huebner, Cytopath ogenic agent resembling human salivary gland virus recovered from tissue cultures of human adenoids, Proc. Soc. Exp. Biol. Med. 94:418–424 (1956).Google Scholar
  4. 4.
    Weller, T. H., Cytomegalovirus: The difficult years, J. Infect. Dis. 122:532–539 (1970).PubMedCrossRefGoogle Scholar
  5. 5.
    Plotkin, S. A., T. Furukawa, N. Zygraich, and C. Huygelen, Candidate cytomegalovirus strain for human vaccination, Infect. Immun. 12:521–527 (1975).PubMedGoogle Scholar
  6. 6.
    Ho, M., Congenital and perinatal human cytomegalovirus infections, in: Cytomegalovirus, Biology and Infection: Current Topics in Infectious Diseases (W. B. Greenough III and T. C. Merigan, eds.), pp. 131–149, Plenum, New York (1982).Google Scholar
  7. 7.
    Griffiths, P. D., A. Campbell-Benzie, and R. B. Heath, A prospective study of cytomegalovirus infection in pregnant women, Br. J. Obstet. Gynecol. 87:308–314 (1980).CrossRefGoogle Scholar
  8. 8.
    Grant, S., E. Edmond, and J. Syme, A prospective study of cytomegalovirus infection in pregnancy. I. Laboratory evidence of congenital infection following maternal primary and reactivated infection, J. Infect. 3:24–31 (1981).PubMedCrossRefGoogle Scholar
  9. 9.
    Stagno, S., R. F. Pass, M. E. Dworsky, R. E. Henderson, E. G. Moore, P. D. Walton, and C. A. Alford, Congenital cytomegalovirus infection. The relative importance of primary and recurrent maternal infection, N. Engl. J. Med. 306:945–949 (1982).PubMedCrossRefGoogle Scholar
  10. 10.
    Melish, M. E., and J. B. Hanshaw, Congenital cytomegalovirus infection: Developmental progress of infants detected by routine screening, Am. J. Dis. Child. 126:190–194 (1973).PubMedGoogle Scholar
  11. 11.
    Saigal, S., O. Lunyk, R. P. B. Larke, and M. A. Chernesky, The outcome in children with congenital cytomegalovirus infection: A longitudinal follow-up study, Am. J. Dis. Child. 136:896–901 (1982).PubMedGoogle Scholar
  12. 12.
    Kumar, M. L., G. A. Nankervis, I. B. Jacobs, C. B. Ernhart, C. E. Glasson, P. M. McMillan, and E. Gold, Congenital and postnatally acquired cytomegalovirus infections: Long-term follow-up, J. Pediatr. 104:674–679 (1984).PubMedCrossRefGoogle Scholar
  13. 13.
    Reynolds, D. W., S. Stagno, K. G. Stubbs, A. J. Dahle, M. M. Livingston, S. S. Saxon, and C. A. Alford, Jr., Inapparent congenital cytomegalovirus infection with elevated IgM levels: Causal relationship with auditory and mental deficiency, N. Engl. J. Med. 290:291–296 (1974).PubMedCrossRefGoogle Scholar
  14. 14.
    Nankervis, G. A., M. L. Kumar, F. E. Cox, and E. Gold, A prospective study of maternal cytomegalovirus infection and its effect on the fetus, Am. J. Obstet. Gynecol. 149:435–440 (1984).PubMedGoogle Scholar
  15. 15.
    Ahlfors, K., M.Forsgren, S.-A. Ivarsson, S. Harris, and L. Svanberg, Congenital cytomegalovirus infection on the relation between type and time of maternal infection and infant’s symptoms, Scand. J. Infect. Dis. 15:129–138 (1983).PubMedGoogle Scholar
  16. 16.
    Monif, G. R. G., E. A. Egan, II, B. Held, and D. V. Eitzman, The correlation of maternal cytomegalovirus infection during varying stages in gestation with neonatal involvement, J. Pediatr. 80:17–20 (1972).PubMedCrossRefGoogle Scholar
  17. 17.
    Stern, H., and S. M. Tucker, Prospective study of cytomegalovirus infection in pregnan cy, Br. Med. J. 2:268–270 (1973).PubMedCrossRefGoogle Scholar
  18. 18.
    Stagno, S., D. W. Reynolds, E. S. Huang, S. D. Thames, R. J. Smith, and C. A. Alford, Jr., Congenital cytomegalovirus infection: Occurrence in an immune population, N. Engl. J. Med. 296:1254–1258 (1977).PubMedCrossRefGoogle Scholar
  19. 19.
    Schopfer, K., E. Laube, and U. Krech, Congenital cytomegalovirus infection in newborn infants of mothers infected before pregnancy, Arch. Dis. Child. 53:536–539 (1978).PubMedCrossRefGoogle Scholar
  20. 20.
    Stagno, S., D. W. Reynolds, A. Tsiantos, D. A. Fuccillo, W. Long, and C. A. Alford, Jr., Comparative serial virologic and serologic studies of symptomatic and subclinical congenitally and naturally acquired cytomegalovirus infections, J. Infect. Dis. 132:568–577 (1975).PubMedCrossRefGoogle Scholar
  21. 21.
    Stagno, S., M. E. Dworsky, J. Tores, T. Mesa, and T. Hirsh, Prevalence and importance of congenital cytomegalovirus infection in three different populations, J. Pediatr. 101:897–900 (1982).PubMedCrossRefGoogle Scholar
  22. 22.
    Reynolds, D. W., P. H. Dean, R. F. Pass, and C. A. Alford, Jr., Specific cell-mediated immunity in children with congenital and neonatal cytomegalovirus infection and their mothers, J. Infect. Dis. 140:493–499 (1979).PubMedCrossRefGoogle Scholar
  23. 23.
    Starr, S. E., M. D. Tolpin, H. M. Friedman, K. Pauker, and S. A. Plotkin, Impaired cellular immunity to cytomegalovirus in congenitally infected children and their mothers, J. Infect. Dis. 140:500–505 (1979).PubMedCrossRefGoogle Scholar
  24. 24.
    Pass, R. F., S. Stagno, W. J. Britt, and C. A. Alford, Specific cell-mediated immunity and the natural history of congenital infection with cytomegalovirus, J. Infect. Dis. 148:953– 961 (1983).PubMedCrossRefGoogle Scholar
  25. 25.
    Okabe, M., S. Chiba, T. Tamura, Y. Chiba, and T. Nakao, Longitudinal studies of cytomegalovirus-specific cell-mediated immunity in congenitally infected infants, Infect. Immun. 41:128–131 (1983).PubMedGoogle Scholar
  26. 26.
    Reynolds, D. W., S. Stagno, T. S. Hosty, M. Tiller, and C. A. Alford, Jr., Maternal cytomegalovirus excretion and perinatal infection, N. Engl. J. Med. 289:1–5 (1973).PubMedCrossRefGoogle Scholar
  27. 27.
    Kumar, M. L., E. Gold, and G. A. Nankervis, Risk of acquired cytomegalovirus infection in infants of maternal CMV excretors, Pediatr. Res. 9:512, 1975.Google Scholar
  28. 28.
    Stagno, S., D. W. Reynolds, R. F. Pass, and C. A. Alford, Jr., Breast milk and the risk of cytomegalovirus infection, N. Engl. J. Med. 302:1073–1074 (1980).PubMedCrossRefGoogle Scholar
  29. 29.
    Numazaki, Y., N. Yano, T. Morizuka, S. Takai, and N. Ishida, Primary infection with human cytomegalovirus: Virus isolation from healthy infants and pregnant women, Am. J. Epidemiol. 91:410–417 (1970).PubMedGoogle Scholar
  30. 30.
    Reynolds, D. W., S. Stagno, R. Reynolds, and C. A. Alford, Jr., Perinatal cytomegalovirus infection: influence of placentally transferred maternal antibody, J. Infect. Dis. 137:564–567 (1978).PubMedCrossRefGoogle Scholar
  31. 31.
    Ballard, R. B., W. L. Drew, K. G. Hufnagle, and P. A. Riedel, Acquired cytomegalovirus infection in pre-term infants, Am. J. Dis. Child. 133:482–485 (1979).PubMedGoogle Scholar
  32. 32.
    Yeager, A. S., P. E. Palumbo, N. Malachowski, R. L. Ariagno, and D. K. Stevenson,Sequelae of maternally derived cytomegalovirus infections in premature infants, J. Pediatr. 102:918–922 (1983).PubMedCrossRefGoogle Scholar
  33. 33.
    Klemola, E., R. von Essen, G. Henle, and W. Henle, Infectious-mononucleosis-like disease with negative heterophile agglutination test. Clinical features in relation to Epstein-Barr virus and cytomegalovirus antibodies, J. Infect. Dis. 121:608–614 (1970).PubMedCrossRefGoogle Scholar
  34. 34.
    Ho, M., Human cytomegalovirus infections in immunosuppressed patients, in: Cytomeg alovirus, Biology and Infection: Current Topics in Infectious Diseases (W. B. Greenough III and T. C. Merigan, eds.), pp. 171–201, Plenum, New York (1982).Google Scholar
  35. 35.
    Dowling, J. N., A. R. Saslow, J. A. Armstrong, and M. Ho, Cytomegalovirus infection in patients receiving immunosuppressive therapy for rheumatologic disorders, J. Infect. Dis. 133:399–408 (1976).PubMedCrossRefGoogle Scholar
  36. 36.
    Pass, R. F., D. W. Reynolds, J. D. Whelchel, A. G. Diethelm, and C. A. Alford, Impaired lymphocyte transformation response to cytomegalovirus and phytohemagglutinin in recipients of renal transplants: Association with antithymocyte globulin, J. Infect. Dis. 143:259–265 (1981).PubMedCrossRefGoogle Scholar
  37. 37.
    Sarov, I., and I. Abody, The morphogenesis of human cytomegalovirus. Isolation and polypeptide characterization of cytomegalovirions and dense bodies, Virology 66:464–473 (1975).PubMedCrossRefGoogle Scholar
  38. 38.
    Kim, K. S., V. Sapienza, R. I. Carp, and H. M. Moon, Analysis of structural polypeptides of purified human cytomegalovirus, J. Virol. 20:604–611 (1976).PubMedGoogle Scholar
  39. 39.
    Stinski, M. F., Synthesis of proteins and glycoproteins in cells infected with human cytomegalovirus, J. Virol. 23:751–767 (1977).PubMedGoogle Scholar
  40. 40.
    Stinski, M. F., Human cytomegalovirus: Glycoproteins associated with virions and dense bodies, J. Virol. 19:594–609 (1976).PubMedGoogle Scholar
  41. 41.
    Farrar, G. H., and J. D. Oram, Characterization of human cytomegalovirus envelope glycoproteins, J. Gen. Virol. 65:1991–2001 (1984).PubMedCrossRefGoogle Scholar
  42. 42.
    Furukawa, T., A. Fioretti, and S. A. Plotkin, Growth characteristics of cytomegalovirus in human fibroblasts with demonstration of protein synthesis early in viral replication, J. Virol. 11:991–997 (1973).PubMedGoogle Scholar
  43. 43.
    Stinski, M. F., Sequence of protein synthesis in cells infected by human cytomegalovirus: Early and late virus-induced polypeptides, J. Virol. 26:686–701 (1978).PubMedGoogle Scholar
  44. 44.
    Stinski, M. F., E. S. Mocarski, D. R. Thomsen, and M. L. Urbanowski, Membrane glycoproteins and antigens induced by human cytomegalovirus, J. Gen. Virol. 43:119– 129 (1979).PubMedCrossRefGoogle Scholar
  45. 45.
    The, T. H., and M. M. A. C. Langenhuysen, Antibodies against membrane antigens of cytomegalovirus infected cells in sera of patients with a cytomegalovirus infection, Clin. Exp. Immunol. 11:475–482 (1972).PubMedGoogle Scholar
  46. 46.
    Kim, K. S., V. J. Sapienza, G.-M. J. Chen, and K. Wisniewski, Production and characterization of monoclonal antibodies specific for a glycosylated polypeptide of human cytomegalovirus, J. Clin. Microbiol. 18:331–343 (1983).PubMedGoogle Scholar
  47. 47.
    Kim, K. S., H. M. Moon, V. Sapienza, and R. I. Carp, Complement-fixing antigen of human cytomegaloviruses, J. Infect. Dis. 135:281–288 (1977).PubMedCrossRefGoogle Scholar
  48. 48.
    Pereira, L., M., Hoffman, D. Gallo, and N. Cremer, Monoclonal antibodies to human cytomegalovirus: Three surface membrane proteins with unique immunological and electrophoretic properties specify cross-reactive determinants, Infect. Immun. 36:924– 932 (1982).PubMedGoogle Scholar
  49. 49.
    Pereira, L.,T.. Hoffman, M. Tatsuno, and D. Dondero, Polymorphism of human cytomegalovirus glycoproteins characterized by monoclonal antibodies, Virolgy 139:73–86 (1984).CrossRefGoogle Scholar
  50. 50.
    Nowak, B., C. Sullivan, P. Sarnow, R. Thomas, F. Bricout, J. C. Nicolas, B. Fleckenstein, and A. J. Levine, Characterization of monoclonal antibodies and polyclonal immune sera directed against human cytomegalovirus virion proteins, Virology 132:325–338 (1984).PubMedCrossRefGoogle Scholar
  51. 51.
    Rasmussen, L. E., R. M. Nelson, D. C. Kelsall, and T. C. Merigan, Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus, Proc. Natl. Acad. Sci. U.S.A. 81:876–880 (1984).PubMedCrossRefGoogle Scholar
  52. 52.
    Rasmussen, L., J. Mullenax, R. Nelson, and T. C. Merigan, Viral polypeptides detected by a complement-dependent neutralizing murine monoclonal antibody to human cytomegalovirus, J. Virol. 55:274–280 (1985).PubMedGoogle Scholar
  53. 53.
    Britt, W. J., Neutralizing antibodies detect a disulfìde-linked glycoprotein complex with in the envelope of human cytomegalovirus, Virology ,135:369–378 (1984).PubMedCrossRefGoogle Scholar
  54. 54.
    Britt, W. J., and D. Auger, Synthesis and processing of the envelope gp 55–116 complex of human cytomegalovirus, J. Virol. 58:185–191 (1986).PubMedGoogle Scholar
  55. 55.
    Furukawa, T., E., Hornberger, S. Sakuma, and S. A. Plotkin, Demonstration of immunoglobulin G receptors induced by human cytomegalovirus, J. Clin. Microbiol. 2:332– 336 (1975).PubMedGoogle Scholar
  56. 56.
    Westmoreland, D., S. St. Jeor, and F. Rapp, The development of cytomegalovirus infected cells binding affinity for normal human immunoglobulin, J. Immunol. 116:1566– 1570 (1976).PubMedGoogle Scholar
  57. 57.
    Osborn, J. E., and D. N. Medearis, Jr., Suppression of interferon and antibody and multiplication of Newcastle disease virus in cytomegalovirus infected mice, Proc. Soc. Exp. Biol. Med. 124:347–353 (1967).PubMedGoogle Scholar
  58. 58.
    Osborn, J. E., A. A. Blazkovec, and D. L. Walker, Immunosuppression during acute murine cytomegalovirus infection, J. Immunol. 100:835–844 (1968).PubMedGoogle Scholar
  59. 59.
    Waner, J. L., Partial characterization of a soluble antigen preparation from cells infected with human cytomegalovirus: Properties of antisera prepared to the antigen, J. Immunol. 114:1454–1457 (1975).PubMedGoogle Scholar
  60. 60.
    Pereira, L., M., Hoffman, and N. Cremer, Electrophoretic analysis of polypeptides immune precipitated from cytomegalovirus-infected cell extracts by human sera, Infect. Immun. 36:933–942 (1982).PubMedGoogle Scholar
  61. 61.
    Cremer, N. E., M. Hoffman, and E. H. Lennette, Analysis of antibody assay methods and classes of viral antibodies in serodiagnosis of cytomegalovirus infection, /. Clin. Microbiol. 8:153–159 (1978).PubMedGoogle Scholar
  62. 62.
    Waner, J. L., T. H. Weller, and S. V. Kevy, Patterns of cytomegalovirus complement-fixing antibody activity: A longitudinal study of blood donors, J. Infect. Dis. 127:538–543 (1973).PubMedCrossRefGoogle Scholar
  63. 63.
    Linde, G. A., L. Hammarstrom, M. A. A. Persson, C. I. E. Smith, V.-A. Sundqvist, and B. Wahren, Virus-specific antibody activity of different subclasses of immunoglobulins G and A in cytomegalovirus infections, Infect. Immun. 42:237–244 (1983).PubMedGoogle Scholar
  64. 64.
    Pereira, L., S. Stagno, M. Hoffman, and J. E. Volanakis, Cytomegalovirus-infected cell polypeptides immuneprecipitated by sera from children with congenital and perinatal infections, Infect. Immun. 39:100–108 (1983).PubMedGoogle Scholar
  65. 65.
    Waner, J. L., D. R. Hopkins, T. H. Weller, and E. N. Allred, Cervical excretion of cytomegalovirus: Correlation with secretory and humoral antibody. J. Infect. Dis. 136:805–809 (1977).PubMedCrossRefGoogle Scholar
  66. 66.
    Tamura, T., S. Chiba, Y. Chiba, and T. Nakao, Virus excretion and neutralizing antibody response in saliva in human cytomegalovirus infection. Infect. Immun. 29:842–845 (1980a).PubMedGoogle Scholar
  67. 67.
    van Loon, A. M., J. T. M. van der Logt, F. W. A. Heessen, and J. van der Veen, Quantitation of immunoglobulin E antibody to cytomegalovirus by antibody capture enzyme-linked immunosorbent assay, J. Clin. Microbiol. 21:558–561 (1985).PubMedGoogle Scholar
  68. 68.
    Weller, T. H., J. B. Hanshaw, and D. E. Scott, Serologic differentiation of viruses responsible for cytomegalic inclusion disease, Virology 12:130–132 (1960).PubMedCrossRefGoogle Scholar
  69. 69.
    Rundell, B. B., and R. F. Betts, Interaction of cytomegalovirus immune complexes with host cells, Infect Immun. 3:658–665 (1981).Google Scholar
  70. 70.
    Betts, R. F., and B. B. Rundell, Physical properties of cytomegalovirus immune complexes prepared with IgG neutralizing antibody anti-IgG, and complement, J. Immunol. 124:337–342 (1980).PubMedGoogle Scholar
  71. 71.
    Middledorp, J. M., J. Jongsma, and T. H. The, Immunity to human cytomegalovirus (HCMV). II. Latently-infected donors have high levels ot T cell memory to HCMV-specifíc membrane antigens (CMV-MA) in the absence of detectable antibodies to CMV-MA, in: CMV: Pathogenesis and Prevention of Human Infection (S. A. Plotkin, S. Michelson, J. S. Pagano, and F. Rapp, eds.), pp. 445–449, Liss, New York (1984).Google Scholar
  72. 72.
    Betts, R. F., and S. G. Schmidt, Cytolytic IgM antibody to cytomegalovirus to primary cytomegalovirus infection in humans, J. Infect. Dis. 143:821–826 (1981).PubMedCrossRefGoogle Scholar
  73. 73.
    Middeldorp, J. M., J. Jongsma, and T. H. The, Killing of human cytomegalovirus-infected fibroblasts by antiviral antibody and complement, J. Infect. Dis. 153:48–55 (1986).PubMedCrossRefGoogle Scholar
  74. 74.
    Middeldorp, J. M., J. Jongsma, and T. H. The, Cytomegalovirus early and late membrane antigens detected by antibodies in human convalescent sera, J. Virol. 54:240–244 (1985).PubMedGoogle Scholar
  75. 75.
    Stagno, S., J. E. Volanakis, D. W. Reynolds, R. Stroud, and C. A. Alford, Jr., Immune complexes in congenital and natal cytomegalovirus infections of man, /. Clin. Invest. 60:838–845 (1977).PubMedCrossRefGoogle Scholar
  76. 76.
    Condie, R. M., B. L. Hall, and R.J. Howard, Treatment of life threatening infections in renal transplant recipients with high dose intravenous human IgG, Transplant Proc. 11:66–72 (1979).PubMedGoogle Scholar
  77. 77.
    Winston, D. J., R. B. Pollard, W. G. Ho, J. G. Gallagher, L. E. Rasmussan, S. N.-Y. Huang, C.-H. Lin, T. G. Gossett, T. C. Merigan, and R. P. Gala, Cytomegalovirus immune plasma in bone marrow transplant recipients, Ann. Intern. Med. 97:11 18 (1982).PubMedGoogle Scholar
  78. 78.
    Myers, J. D., J. Lesczynski, J. A. Zaia, N. Flournoy, B. Newton, D. R. Szydman, G. G. Wright, M. J. Levin, and E. D. Thomas, Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation, Ann. Intern. Med. 98:442–446 (1983).Google Scholar
  79. 79.
    Condie, R. M., and R.J. O’Reilly, Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native, unmodified cytomegalovirus globulin. Randomized trial in bone marrow transplant recipients, Am. J. Med. 76:(3A):124–141 (1984).CrossRefGoogle Scholar
  80. 80.
    Møller-Larsen, A., H. K. Anderson, I. Heron, and I. Sarov, In vitro stimulation of human lymphocytes by purified CMV, Intervirology 6:249–257 (1975/76).PubMedCrossRefGoogle Scholar
  81. 81.
    Ten Napel, C. H. H., T. H. The, J. Bijker, G. C. DeGast, and M. M. A. C. Langenhuysen, Cytomegalovirus-directed lymphocyte reactivity in healthy adults tested by a cytomega-lovirus-induced lymphocyte transformation test, Clin. Exp. Immuno. 29:52–60 (1977).Google Scholar
  82. 82.
    Waner, J. L., and J. E. Budnick, Blastogenic response of human lymphocytes to human cytomegalovirus, Clin. Exp. Immuno. 30:44–49 (1977).Google Scholar
  83. 83.
    Wahren, B., K.-H. Robert, and S. Nordlund, Conditions for cytomegalovirus stimulation of lymphocytes, Scand. J. Immunol. 13:581–586 (1981).PubMedCrossRefGoogle Scholar
  84. 84.
    Schirm, J., H. W. Roenhorst, and T. H. The, Comparison of in vitro lymphocyte proliferations induced by cytomegalovirus-infected human fibroblasts and cell-free cytomegalovirus, Infect. Immun. 30:621–627 (1980).PubMedGoogle Scholar
  85. 85.
    Roenhorst, H. W., J. M. Middledorp, J. M. Beelen, J. Schirm, A. M. Tegzess, and T. H. The, Maintenance of cytomegalovirus (CMV) latency and host immune responses of long-term renal allograft survivors. I. Prolonged suppression of in vitro lymphocyte responses against CMV infected fibroblasts related to previous secondary CMV infection, Clin. Exp. Immunol. 59:709–715 (1985).PubMedGoogle Scholar
  86. 86.
    Beutner, K. R., A. Morag, R. Deibel, B. Morag, D. Raiken, and P. L. Ogra, Strain-specific local and systemic cell-mediated immune responses to cytomegalovirus in humans, Infect. Immun. 20:82–87 (1978).PubMedGoogle Scholar
  87. 87.
    Starr, S. E., B. Dalton, T. Garrabrant, K. Paucker, and S. A. Plotkin, Lymphocyte blastogenesis and interferon production in adult human leukocyte cultures stimulated with cytomegalovirus antigens, Infect. Immun. 30:17–22 (1980).PubMedGoogle Scholar
  88. 88.
    Ten Napel, C. H. H., and T. H. The, Acute cytomegalovirus infection and the host immune response. I. Development and maintenance of cytomegalovirus induced in vitro lymphocyte reactivity and its relationship to production of cytomegalovirus antibodies, Clin. Exp. Immunol. 39:263–271 (1980).PubMedGoogle Scholar
  89. 89.
    Waner, J. L., N. Kong, and S. Biano, Blastogenic response of human lympho cytes to early antigen(s) of human cytomegalovirus, Infect. Immun. 41:1084–1088 (1983).PubMedGoogle Scholar
  90. 90.
    Rinaldo, C. R., Jr., P. H. Black, and M. S. Hirsch, Interactions of cytomegalovirus with leukocytes from patients with mononucleosis due to cytomegalovirus, J. Infect. Dis. 136:667–678 (1977).PubMedCrossRefGoogle Scholar
  91. 91.
    Carney, W. P., R. H. Rubin, R. A. Hoffman, W. P. Hansen, K. Healey, and M. S. Hirsch, Analysis of T lymphocyte subsets in cytomegalovirus mononucleosis, J. Immunol. 126:2114–2116 (1981).PubMedGoogle Scholar
  92. 92.
    Levin, M. J., C. R. Rinaldo, Jr., P. L. Leary, J. A. Zaia, and M. S. Hirsch, Immune response to herpesvirus antigens in adults with acute cytomegaloviral mononucleosis, J. Infect. Dis. 140:851–857 (1979).PubMedCrossRefGoogle Scholar
  93. 93.
    Gehrz, R. C., S. C. Marker, S. O. Knorr, J. M. Kalis, and H. H. Balfour, Jr., Specific cell-mediated immune defect in active cytomegalovirus infection of young children and their mothers, Lancet 2:844–847 (1977).PubMedCrossRefGoogle Scholar
  94. 94.
    Gehrz, R. C., W. R. Christianson, K. M. Linner, M. M. Conroy, S. A. McCue, and H. H. Balfour, Jr., Cytomegalovirus-specifìc humoral and cellular immune responses in human pregnancy, J. Infect. Dis 143:391–395 (1981).PubMedCrossRefGoogle Scholar
  95. 95.
    Faix, R. G., S. E. Zweig, J. F. Kummer, D. Moore, and D. J. Lang, Cytomegalovirus-specifìc cell-mediated immunity during pregnancy in lower socioeconomic class adolescents,/ Infect. Dis. 148:621–629 (1983).PubMedCrossRefGoogle Scholar
  96. 96.
    Diamond, R. D., R. Keller, G. Lee, and D. Finkel, Lysis of cytomegalovirus-infected human fibroblasts and transformed human cells by peripheral blood-lymphoid cells from normal human donors, Proc. Soc. Exp. Biol. Med. 154:259–364 (1977).PubMedGoogle Scholar
  97. 97.
    Kirmani, N., R. K. Ginn, K. K. Mittal, J. F. Manischewitz, and G. V. Quinnan, Jr., Cytomegalovirus-specifìc cytotoxicity mediated by non-T lymphocytes from peripheral blood of normal volunteers, Infect. Immun. 34:441–447 (1981).PubMedGoogle Scholar
  98. 98.
    Starr, S. E., and T. Garrabrant, Natural killing of cytomegalovirus-infected fibroblasts by human mononuclear leukocytes, Clin. Exp. Immunol. 46:484–492 (1981).PubMedGoogle Scholar
  99. 99.
    Waner, J. L., and J. A. Nierenberg, Natural killing (NK) of cytomegalovirus (CMV)-infected fibroblasts: A comparison between two strains of CMV, uninfected fibroblasts and K562 cells, J Med. Virol. 16:233–244 (1985).PubMedCrossRefGoogle Scholar
  100. 100.
    Borysiewicz, L. K., B. Rodgers, S. Morris, S. Graham, and J. G. P. Sissons, Lysis of human cytomegalovirus infected fibroblasts by natural killer cells: Demonstration of an interferon-independent component requiring expression of early viral proteins and characterization of effector cells, J. Immunol. 134:2695–2701 (1985).PubMedGoogle Scholar
  101. 101.
    Rola-Pleszczynski, M., L. D. Frenkel, D. A. Fuccillo, S. A. Hensen, M. M. Vincent, D. W. Reynolds, S. Stagno, and J. A. Bellanti, Specific impairment of cell-mediated immunity in mothers of infants with congenital infection due to cytomegalovirus, J Infect Dis. 135:386–391 (1977).PubMedCrossRefGoogle Scholar
  102. 102.
    Harrison, C. J., and J. L. Waner, Natural killer cell activity in infants and children excreting cytomegalovirus, J. Infect. Dis. 151:301–307 (1985).PubMedCrossRefGoogle Scholar
  103. 103.
    Starr, S. E., L. Smiley, C. Wlodaver, H. M. Friedman, S. A. Plotkin, and C. Barker, Natural killing of cytomegalovirus-infected targets in renal transplant recipients, Transplantation 37:161–164 (1984).PubMedCrossRefGoogle Scholar
  104. 104.
    Rinaldo, C. R., Jr., M. Ho, W. H. Hamoudi, X.-E. Gui, and R. L. DeBiasio, Lymphocyte subsets and natural killer cell responses during cytomegalovirus mononucleosis, Infect. Immun. 40:472–477 (1983).PubMedGoogle Scholar
  105. 105.
    Quinnan, G. V., Jr., N. Kirmani, A. H. Rook, J. F. Manischewitz, L.Jackson, G. Moreschi, G. W. Santos, R. Saral, and W. B. Burns, HLA-restricted T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients, N. Engl. J. Med. 307:7–13 (1982).PubMedCrossRefGoogle Scholar
  106. 106.
    Quinnan, G. V., and J. E. Manischewitz, The role of natural killer cells and antibody dependent cell-mediated cytotoxicity during murine cytomegalovirus infection, J. Exp. Med. 150:1549–1554 (1979).PubMedCrossRefGoogle Scholar
  107. 107.
    Bukowski, J. F., B. A. Woda, and R. M. Welsh, Pathogenesis of murine cytomegalovirus infection in natural killer cell-depleted mice, J. Virol. 52:119–128 (1984).PubMedGoogle Scholar
  108. 108.
    Selgrade, M. K., and J. E. Osborn, Role of macrophages in resistance to murine cytomegalovirus, Infect. Immun. 10:1383–1390 (1974).PubMedGoogle Scholar
  109. 109.
    Chalmer, J. E., J. S. Mackenzie, and N. F. Stanley, Resistance to murine cytomegalovirus linked to the major histocompatibility complex of the mouse, J. Gen. Virol. 37:107–114 (1977).PubMedCrossRefGoogle Scholar
  110. 110.
    Bancroft, G. J., G. R. Shellam, and J. E. Chalmer, Genetic influences on the augmenta tion of natural killer (NK) cells during murine cytomegalovirus infection: Correlation with patterns of resistance, J. Immunol. 126:988–994 (1981).PubMedGoogle Scholar
  111. 111.
    Shellam, G. R., J. E. Allan, J. M. Papadimitriou, and G. J. Bancroft, Increased susceptibility to cytomegalovirus infection in beige mutant mice, Proc. Natl. Acad. Sci. USA 78:5104–5108 (1981).PubMedCrossRefGoogle Scholar
  112. 112.
    Kay, H. D., G. D. Bonnard, W. H. West, and R. B. Herberman, A functional comparison of human Fc-receptor bearing lymphocytes active in natural cytotoxicity and antibody-dependent cellular cytotoxicity, J. Immunol. 118:2058–2066 (1977).PubMedGoogle Scholar
  113. 113.
    Quinnan, G. V., N. Kirmani, E. Esber, R. Saral, J. E. Manischewitz, J. L. Rogers, A. H. Rook, G. W. Santos, and W. H. Burns, HLA-restricted cytotoxic T lymphocyte and non-thymic cytotoxic lymphocyte responses to cytomegalovirus infections of bone marrow transplant recipients, J. Immunol. 126:2036–2041 (1981).PubMedGoogle Scholar
  114. 114.
    Borysiewicz, L. K., S. Morris, J. D. Page, and J. G. P. Sissons, Human cytomegalovirus-specific cytotoxic T lymphocytes: Requirements for in vitro generation and specificity, Eur. J. Immunol. 13:804–809 (1983).PubMedCrossRefGoogle Scholar
  115. 115.
    Gehrz, R. C., and S. R. Rutzick, Cytomegalovirus (CMV)-specific lysis of CMV-infected target cells can be mediated by both NK-like and virus-specific cytotoxic T lymphocytes, Clin. Exp. Immunol. 61:80–89 (1985).PubMedGoogle Scholar
  116. 116.
    Quinnan, G. V., Jr., W. H. Burns, N. Kirmani, A. H. Rook,J. Manischewitz, L.Jackson, G. W. Santos, and R. Saral, HLA-restricted cytotoxic T lymphocytes are an early immune response and important defense mechanism in cytomegalovirus infections, Rev. Infect. Dis. 6:156–163 (1984).PubMedCrossRefGoogle Scholar
  117. 117.
    Rook, A. H., G. V. Quinnan, Jr., W. J. R. Fredericks. F. Manischewitz, and N. Kirmani, Importance of cytotoxic lymphocytes during cytomegalovirus infection in renal transplant recipients, Am. J. Med. 76:385–392 (1984).PubMedCrossRefGoogle Scholar
  118. 118.
    Felsenstein, D., W. P. Carney, V. R. Iacoviello, and M. S. Hirsch, Phenotypic properties of atypical lymphocytes in cytomegalovirus-induced mononucleosis, J. Infect. Dis. 152:198–203 (1985).PubMedCrossRefGoogle Scholar
  119. 119.
    Maher, P., C. M. O’Toole, T. G. Wreghitt, D. J. Spiegelhalter, and T. A. H. English, Cytomegalovirus infection in cardiac transplant recipients associated with chronic T cell subset ratio inversion with expansion of Leu-7 + Ts_c+ subset, Clin. Exp. Immunol. 62:615–624 (1985).Google Scholar
  120. 120.
    Pass, R. F., M. A. Roper, and A. M. August, T lymphocyte subpopulations in congenital cytomegalovirus infection, Infect. Immun. 41:1380–1382 (1983).PubMedGoogle Scholar
  121. 121.
    Fiala, M., J. E. Payne, T. V. Berne, T. C. Moore, W. Henle, J. Z. Montgomerie, S. N. Chatterjee, and L. B. Guze, Epidemiology of cytomegalovirus infection after transplan tation and immunosuppression, J. Infect. Dis. 132:421–433 (1975).PubMedCrossRefGoogle Scholar
  122. 122.
    Winston, D. J., W. G. Ho, C. L. Howell, M. J. Miller, R. Mickey, W. J. Martin, C. Lin, and R. P. Gale, Cytomegalovirus infections associated with leukocyte transfusions. Ann. Intern. Med. 93:671–675 (1980).PubMedGoogle Scholar
  123. 123.
    Diosi, P., E. Moldovan, and N. Tomescu, Latent cytomegalovirus infection in blood donors, Br. Med. J. 4:660–662 (1969).PubMedCrossRefGoogle Scholar
  124. 124.
    Schrier, R. D., J. A. Nelson, and M. B. A. Oldstone, Detection of human cytomegalovirus in peripheral blood lymphocytes in a natural infection, Science 230:1048–1051 (1985).PubMedCrossRefGoogle Scholar
  125. 125.
    St. Jeor, S., and A. Weisser, Persistence of cytomegalovirus in human lymphoblasts and peripheral leukocyte cultures, Infect. Immun. 15:402–409 (1977).Google Scholar
  126. 126.
    Furukawa, T., N. Yoshimura, J. H. Jean, and S. A. Plotkin, Chronically persistent infection with human cytomegalovirus in human lymphoblasts, J. Infect. Dis. 139:211–214 (1979).PubMedCrossRefGoogle Scholar
  127. 127.
    Tocci, M. J., and S. C. St. Jeor, Susceptibility of lymphoblastoid cells to infection with human cytomegalovirus, Infect. Immun. 23:418–423 (1979).PubMedGoogle Scholar
  128. 128.
    Tocci, M. J., and S. C. St. Jeor, Persistence and replication of the human cytomegalovirus genome in lymphoblastoid cells of B and T origin, Virology 96:664–668 (1979).PubMedCrossRefGoogle Scholar
  129. 129.
    Einhorn, L., and A. Ost, Cytomegalovirus infection of human blood cells, J. Infect. Dis. 149:207–214 (1984).PubMedCrossRefGoogle Scholar
  130. 130.
    Rice, G. P. A., R. D. Schrier, and M. B. A. Oldstone, Cytomegalovirus infects human lymphocytes and monocytes: Virus expression is restricted to immediate-early gene products, Proc. Natl. Acad. Sci. USA 81:6134–6138 (1984).PubMedCrossRefGoogle Scholar
  131. 131.
    Sing, G. K., and H. M. Garnett, The effects of human cytomegalovirus challenge in vitro on subpopulations of T cells from seronegative donors, J. Med. Virol 14:363–371 (1984).PubMedCrossRefGoogle Scholar
  132. 132.
    Hutt-Fletcher, L. M., N. Balachandran, and M. H. Elkins, B cell activation by cytomegalovirus, J. Exp. Med. 158:2171–2176 (1983).PubMedCrossRefGoogle Scholar
  133. 133.
    Yachie, A., G. Tosato, S. E. Straus, and R. M. Blaese, Immunostimulation by cytomegalovirus (CMV): Helper T cell-dependent activation of immunoglobulin production in vitro by lymphocytes from CMV-immune donors, J. Immunol. 135:1395–1400 (1985).PubMedGoogle Scholar
  134. 134.
    Rinaldo, C. R., Jr., W. P. Carney, B. S. Richter, P. H. Black, and M. S. Hirsch, Mechanisms of immunosuppression in cytomegaioviral mononucleosis, J. Infect. Dis. 141:488–495 (1980).PubMedCrossRefGoogle Scholar
  135. 135.
    Carney, W. P., and M. S. Hirsch, Mechanisms of immunosuppression in cytomegalovirus mononucleosis. II. Virus-monocyte interactions, J. Infect. Dis. 144: 47–54 (1981).PubMedCrossRefGoogle Scholar
  136. 136.
    Rodgers, B. C., D. M. Scott, J. Mundin, and J. G. P. Sissons, Monocyte-derived inhibitor of interleukin 1 induced by human cytomegalovirus, J. Virol. 55: 527–532 (1985).PubMedGoogle Scholar
  137. 137.
    Drew, W. L., M. A. Conant, R. C. Miner, E. S. Huang, J. L. Ziegler, J. R. Groundwater, J. H. Gullett, P. Volberding, D. I. Abrams, and L. Mintz, Cytomegalovirus and Kaposis sarcoma in young homosexual men, Lancet 2:125–127 (1982).PubMedCrossRefGoogle Scholar
  138. 138.
    Macher, A. M., C. M. Reichert, S. E. Straus, D. L. Longo, J. Parrillo, H. C. Lane, and A. S. Fauci, Death in the AIDS patient: Role of cytomegalovirus, (Letter.) N. Engl. J. Med. 309:1454 (1983).PubMedGoogle Scholar
  139. 139.
    Quinnan, G. V. Jr., H. Masur, A. H. Rook, G. Armstrong, W. R. Fredericks. Epstein, J. F. Manischewitz, A. M. Macher, L. Jackson, J. Ames, H. A. Smith, M. Parker, G. R. Pearson, J. Parrillo, C. Mitchell, and S. E. Straus, Herpesvirus infections in the acquired immune deficiency syndrome, JAMA 252:72–77 (1984).PubMedCrossRefGoogle Scholar
  140. 140.
    Hirsch, M. S., R. T. Schooley, D. D. Ho, and J. C. Kaplan, Possible viral interactions in the acquired immunodeficiency syndrome (AIDS), Rev. Infect. Dis. 6:726–731 (1984).PubMedCrossRefGoogle Scholar
  141. 141.
    Kari, B., N. Lussenhop, R. Goertz, M. Wabuke-Bunoti, R. Radeke, and R. Gehrz, Characterization of monoclonal antibodies reactive to several biochemically distinct human cytomegalovirus glycoprotein complexes, J. Virol. 60:345–352 (1986).PubMedGoogle Scholar
  142. 142.
    Cranage, M. P., T. Kouzarides, A. T. Bankier, S. Satchwell, K. Weston, P. Tomlinson, B. Barrell, H. Hart, S. E. Bell, A. C. Minson, and G. L. Smith, Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus, EMBO. 5:3057–3063 (1986).Google Scholar
  143. 143.
    Gold, D., R. Ashley, H. H. Handsfield, M. Verdon, L. Leach, J. Mills, L. Drew, and L. Corey, Immunoblot analysis of the humoral immune response in primary cytomegalovi rus infection, J Infect. Dis. 157:319–326 (1988).PubMedCrossRefGoogle Scholar
  144. 144.
    Zaia, J., S. J. Forman, Y-P. Ting, E. Vanderwal-Urbina, and K. G. Blume. Polypeptide-specific antibody response to human cytomegalovirus after infection in bone marrow transplant recipients, J. Infect Dis. 153:780–787 (1986).PubMedCrossRefGoogle Scholar
  145. 145.
    Schrier, R. D., and M. B. A. Oldstone, Recent clinical isolates of cytomegalovirus suppress human cytomegalovirus-specific human leukocyte antigen-restricted cytotoxic T-lymphocyte activity, J. Virol. 59:127–131 (1986).PubMedGoogle Scholar
  146. 146.
    Braun, R. W., and H. C. Reiser, Replication of human cytomegalovirus in human peripheral blood T cells, J. Virol. 60:29–36 (1986).PubMedGoogle Scholar
  147. 147.
    Dudding, L. R., and H. M. Garnett, Interaction of strain AD 169 and a clinical isolate of cytomegalovirus with peripheral monocytes: The effect of lipopolysaccharide stimulation, J. Infect. Dis. 155:891–896 (1987).PubMedCrossRefGoogle Scholar
  148. 148.
    Weinshenker, B. G., W. Sharon, and G. P. A. Rice, Phorbol ester-induced differentiation permits productive human cytomegalovirus infection in a monocyte cell line, J. Immunol. 140:1625–1631 (1988).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • Joseph L. Waner
    • 1
    • 2
  1. 1.Department of Pediatrics, Health Sciences CenterUniversity of OklahomaOklahoma CityUSA
  2. 2.Virology LaboratoryOklahoma Children’s Memorial HospitalOklahoma CityUSA

Personalised recommendations